L'intérêt à découvert pour NovoCure donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de NovoCure. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

NovoCure (NASDAQ:NVCR) Stock, Rapport sur les intérêts à découvert

NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

Zimmer Biomet Holdings, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zbh#NYSE">ZBH</a>) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.
In the last reported quarter, the company&#39;s earnings of $2.01 beat the Zacks Consensus Estimate by 1.5%. ZBH beat on earnings in each of the trailing four quarters, the average surprise being 2.84%.
<h2>ZBH&#39;s Q3 Estimates</h2>
The Zacks Consensus Estimate for revenues is pegged at $1.81 billion, suggesting a 3.3% rise from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $1.75 per share, indicating a 6.1% improvement from the year-ago reported numbers.
<h2>Estimate Revision Trend Ahead of ZBH&#39;s Q3 Earnings</h2>
The Zacks Consensus Estimate for earnings has moved south 1.1%&nbsp; to $1.75 per share in the past 30 days.
Let&#39;s briefly look at how things might have shaped up for this MedTech major in the to-be-reported quarter.
<h2>Factors at Play</h2>
Zimmer Biomet is likely to have experienced strong growth in the&nbsp;third quarter on the back of strong performance from its business segments.
The Hip business is expected to have witnessed growth due to the company&#39;s comprehensive suite of solutions in navigation in direct anterior stems and surgical impactors.
While this business lagged&nbsp;the broader market during the second quarter due to key portfolio gaps, the company has made significant progress with new product introductions. During the same quarter, Zimmer Biomet launched the&nbsp;surgical impactor HAMMR, whose adoption has been great so far. Additionally, during the&nbsp;third-quarter, the company entered into a definitive agreement to acquire OrthoGrid Systems, Inc. The acquisition includes OrthoGrid&#39;s AI-powered, fluoroscopy-based surgical assistance platform&nbsp;Hip AI, as well as two additional FDA-cleared orthopedic applications and over 40 patents.
Outside the United States, ZBH expects to launch a second generation of hip posterior robotics. Banking on these developments, the company is expected to report a strong revenue increase within this category in the third quarter.
Within the Knees business, the company faced some challenges from a supply standpoint. These are high ASP cases.
<h2>Zimmer Biomet Holdings, Inc. Price and EPS Surprise</h2>
<div class="chart_embed"><img alt="Zimmer Biomet Holdings, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/50/1729087518.png" style="height:263px; width:544px" title="" />
Zimmer Biomet Holdings, Inc. price-eps-surprise | Zimmer Biomet Holdings, Inc. Quote
</div>
Although this business in the United States was softer than expected, the company delivered knee growth of 5% year over year in the second quarter. We expect this growth trend to have continued in the third quarter as well.&nbsp;
The company expects to launch two different ROSA for knees in the coming three to eight quarters. In addition to ROSA, Zimmer Biomet has a partnership with THINK Surgical for TMINI &mdash; a&nbsp;miniature handheld robotic system for total knee arthroplasty. TMINI was supposed to be released in the second half of 2024. These developments might have had a positive impact on the company&#39;s third-quarter top-line performance.
In the second quarter, the S.E.T business grew mid-single digits, led by key focus areas of CMFT, upper extremities and sports growing on average high-single digits. The second quarter of 2024 was the third quarter in a row to experience such growth. Every single business within S.E.T. grew for the first time in the&nbsp;second quarter. We expect this trend to have continued in the third quarter as well.
<h2>What Our Model Suggests for ZBH</h2>
Per our proven model, a stock with a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Zimmer Biomet has an Earnings ESP of -1.65%%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Strong).
<h2>Stocks Worth a Look</h2>
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Atea Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avir#NASDAQ">AVIR</a>) has an Earnings ESP of +13.13% and a Zacks Rank #1 at present.
The company is expected to release third-quarter 2024 results on Nov. 13. AVIR&#39;s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 5.23%.
RadNet&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>)&nbsp;has an Earnings ESP of +20.00% and a Zacks Rank #2 at present. The company is expected to release third-quarter 2024 results on Nov. 13.
RDNT&#39;s earnings surpassed estimates in three of the trailing four quarters and broke even once, the average surprise being 98.23%. The Zacks Consensus Estimate for RadNet&#39;s third-quarter EPS is expected to increase 21.4% from the year-ago quarter&#39;s reported numbers.
TransMedics Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) has an Earnings ESP of +26.63% and a Zacks Rank #3 at present. The company is likely to release third-quarter 2024 results on Nov. 4. The Zacks Consensus Estimate for the company&#39;s third-quarter EPS implies a surge of 333.3% from the year-ago quarter&#39;s reported figure.
<a href="https://www.zacks.com/stock/news/2351618/zbh-gears-up-for-q3-earnings-what-lies-ahead-for-the-stock?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2351618">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

AVIR

RDNT

TMDX

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

It's no secret that cannabis companies are facing some formidable challenges when it comes to raising capital, thanks to marijuana&#8217;s onerous classification as a <a href="https://www.benzinga.com/markets/cannabis/24/02/36916329/is-marijuana-a-controlled-substance-wait-what-is-a-controlled-substance" target="_blank" rel="noreferrer noopener">Schedule I controlled substance</a> under federal law. But now with potential changes on the horizon, such as cannabis rescheduling and banking reform, more companies just might improve their financial positions and attract new investments.
Even now, in anticipation of potential regulatory changes, there's been an increase in capital raises. Frank Colombo, managing director of data analytics and investment banking at Viridian Capital Advisors, provided an overview of capital raising trends the <a href="https://www.benzinga.com/markets/cannabis/24/10/41297836/exclusive-tracking-every-cannabis-deal-is-a-lot-of-fun-says-financial-expert-behind-essential-in">Benzinga Cannabis Capital Conference</a>. He told the crowd gathered in Chicago there&#8217;s been an increase of 14.8% in capital raises in 2024, driven mostly by Canadian equities and U.S. debt.
Colombo said U.S. debt accounts for over 50% of capital raises, indicating a reliance on debt financing rather than equity in the market. Retail and cultivation sectors are responsible for half of all capital raises. However, out of 12 different sectors, &#8220;investments in M&amp;A" were &#8220;really up,&#8221; <a href="https://www.benzinga.com/markets/cannabis/24/10/41297836/exclusive-tracking-every-cannabis-deal-is-a-lot-of-fun-says-financial-expert-behind-essential-in">he explained.</a>
<h3 class="wp-block-heading">But Still&#8230;Cannabis Debt Looms</h3>
Green Market Report's Debra Borchardt took a closer look at what she called it "a tsunami of debt headed straight for the cannabis industry," or approximately $1.83 billion of the debt that's due by 2026 that many public marijuana operators opted for earlier as they lacked much-needed capital.
According to regulatory filings for the publicly traded businesses in the industry large cannabis operators Curaleaf Holdings, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>), Trulieve Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) and Verano Holdings (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTCQX">VRNOF</a>) are about to face debt maturities in 2026, <a href="https://www.greenmarketreport.com/tsunami-of-debt-heading-toward-the-biggest-cannabis-companies/">explained</a> Borchardt who was also a guest at Benzinga&#8217;s conference in Chicago.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
While these companies have yet to navigate considerable debt challenges while focusing on their growth and operations, other big players in the space have successfully managed their respective debts, at least for now.
Borchardt highlighted Ascend Wellness Holdings' (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>) and Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) "preemptive actions" to address their growing debt issues while mentioning TerrAscend Corp.&#8217;s (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSND#TSX">TSND</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTCQX">TSNDF</a>) FG Loan which will mature in 2028.
New York-headquartered Ascend closed its <a href="https://www.benzinga.com/markets/cannabis/24/07/39776292/ascend-wellness-to-issue-235m-of-senior-secured-notes-to-prepay-215m-under-term-loan">previously announced</a> private placement of $235 million of 12.75% senior secured notes due 2029 in July with plans to prepay $215 million of principal amounts <a href="https://www.benzinga.com/markets/cannabis/24/07/39839510/ascend-wellness-cannabis-co-closes-235m-private-placement-of-senior-secured-notes-refinances-exi">outstanding under its existing term loan.</a>
Meanwhile, the owner of RISE Dispensaries closed on a $150 million 5-year syndicated credit facility led by Valley National Bank, the principal subsidiary of Valley National Bancorp which will allow it to retire its $225 million <a href="https://www.benzinga.com/markets/cannabis/24/09/40834346/cannabis-giant-green-thumb-secures-150m-credit-facility-strengthens-our-already-clean-balance-sh">senior secured debt due April 30, 2025.</a>
Jason Wild, executive chairman of TerrAscend said the <a href="https://www.benzinga.com/markets/cannabis/24/08/40133450/terrascend-cannabis-wraps-up-140m-debt-financing-no-other-material-debt-maturing-until-2027-says">recent completion</a> of the second and final draw of $26 million as part of its $140 million senior secured term loan, <a href="https://www.benzinga.com/markets/cannabis/24/10/41130165/cannabis-company-terrascend-secures-second-and-final-26m-loan-reduces-debt-in-michigan">enabled the company to have</a> "no other material debt maturing until late 2027."
<h3 class="wp-block-heading">Financial Institutions Set To Earn Billions In Interest Revenue</h3>
A new report from Whitney Economics backed by CTrust and Green Check projects that the U.S. cannabis industry will need between $65.6 billion and $130.7 billion in sustainable growth capital to support new cannabis businesses and help refinance existing ones over the next decade.
On the flip side, the market will generate roughly $1 billion to $2.4 billion in potential interest revenue for financial institutions willing to lend to cannabis businesses, over the same period, <a href="https://www.benzinga.com/markets/cannabis/24/10/41335229/cannabis-industrys-130b-growth-potential-top-states-for-investment-as-financial-institutions-set">according to the report.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41241003/exclusive-cannabis-rescheduling-is-not-cure-all-for-industry-problems-experts-explain-how-tax-ta">Cannabis Industry&#8217;s $130B Growth Potential: Top States For Investment As Financial Institutions Set To Earn Billions In Interest Revenue, New Report Reveals</a></li>
</ul>

Cannabis

Financing

AAWH

CRLBF

CSE:GTII

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

GTII

TCNNF

TRUL

TSNDF

TSX:TSND

VRNOF

Cannabis Debt Looms For These Weed Giants: Here's How Some Tackled Their Financial Challenges

Investors with a lot of money to spend have taken a bearish stance on Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with LRN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Stride.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 44%, bearish.
Out of all of the options we uncovered, 8 are puts, for a total amount of $322,830, and there was 1 call, for a total amount of $101,600.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $80.0 for Stride, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Stride options trades today is 652.86 with a total volume of 2,003.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Stride's big money trades within a strike price range of $55.0 to $80.0 over the last 30 days.
<h3>Stride Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104351_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.0</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$70.00</td>
<td>$101.6K</td>
<td style="text-align: right;">77</td>
<td style="text-align: right;">273</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.4</td>
<td>$2.75</td>
<td>$4.0</td>
<td>$55.00</td>
<td>$80.0K</td>
<td style="text-align: right;">71</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$12.4</td>
<td>$11.4</td>
<td>$11.76</td>
<td>$80.00</td>
<td>$47.0K</td>
<td style="text-align: right;">491</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$5.2</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$65.00</td>
<td>$42.8K</td>
<td style="text-align: right;">712</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>LRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$6.4</td>
<td>$3.7</td>
<td>$4.5</td>
<td>$75.00</td>
<td>$33.3K</td>
<td style="text-align: right;">542</td>
<td style="text-align: right;">84</td>
</tr>
</tbody>
</table>

<h3>About Stride</h3>
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional, and Private Pay Schools and Other.
Following our analysis of the options activities associated with Stride, we pivot to a closer look at the company's own performance.
<h3>Stride's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,840,323, the LRN's price is down by -2.68%, now at $68.7. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Stride</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $90.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barrington Research keeps a Outperform rating on Stride with a target price of $90. 
&#x2A; Maintaining their stance, an analyst from Barrington Research continues to hold a Outperform rating for Stride, targeting a price of $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Stride with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on Stride: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NET usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Cloudflare. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $78,475, and 8 are calls, amounting to $451,000.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $110.0 for Cloudflare over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cloudflare stands at 570.12, with a total volume reaching 1,625.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cloudflare, situated within the strike price corridor from $70.0 to $110.0, throughout the last 30 days.
<h3>Cloudflare 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104346_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$23.65</td>
<td>$22.95</td>
<td>$23.23</td>
<td>$70.00</td>
<td>$76.6K</td>
<td>27</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.95</td>
<td>$21.2</td>
<td>$21.68</td>
<td>$70.00</td>
<td>$71.5K</td>
<td>60</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.68</td>
<td>$2.62</td>
<td>$2.68</td>
<td>$110.00</td>
<td>$67.2K</td>
<td>1.6K</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$3.15</td>
<td>$2.64</td>
<td>$3.15</td>
<td>$90.00</td>
<td>$62.0K</td>
<td>1.2K</td>
<td style="text-align: right;">543</td>
</tr>
<tr>
<td>NET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$94.00</td>
<td>$51.0K</td>
<td>206</td>
<td style="text-align: right;">119</td>
</tr>
</tbody>
</table>

<h3>About Cloudflare</h3>
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
In light of the recent options history for Cloudflare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Cloudflare's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,376,225, the price of NET is down by -2.39%, reaching $91.56.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 22 days from now.</li>
</ul>
<h3>What The Experts Say On Cloudflare</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $65.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Exane BNP Paribas lowers its rating to Underperform with a new price target of $65.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cloudflare with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Cloudflare

High-rolling investors have positioned themselves bullish on Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ESTC often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Elastic. This is not a typical pattern.
The sentiment among these major traders is split, with 33% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $72,250, and 8 calls, totaling $493,658.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $85.0 for Elastic over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Elastic's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Elastic's whale trades within a strike price range from $80.0 to $85.0 in the last 30 days. 
<h3>Elastic Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729104341_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.5</td>
<td>$9.7</td>
<td>$80.00</td>
<td>$184.2K</td>
<td>1.2K</td>
<td style="text-align: right;">330</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$9.7</td>
<td>$9.5</td>
<td>$9.6</td>
<td>$80.00</td>
<td>$98.8K</td>
<td>1.2K</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>ESTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.5</td>
<td>$8.4</td>
<td>$8.5</td>
<td>$85.00</td>
<td>$72.2K</td>
<td>124</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$10.1</td>
<td>$80.00</td>
<td>$64.6K</td>
<td>1.2K</td>
<td style="text-align: right;">521</td>
</tr>
<tr>
<td>ESTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$80.00</td>
<td>$33.9K</td>
<td>1.2K</td>
<td style="text-align: right;">365</td>
</tr>
</tbody>
</table>

<h3>About Elastic</h3>
Elastic is a software company based in Mountain View, California, focusing on search-adjacent products. Its search engine allows it to process both structured and unstructured data while gleaning insights from that data. The firm's primary focus is on enterprise search, observability, and security.
After a thorough review of the options trading surrounding Elastic, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Elastic Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 314,355, the ESTC's price is up by 0.66%, now at $82.72. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Elastic with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ESTC

Market Whales and Their Recent Bets on ESTC Options

WIIM

MoneyLion shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform rating and announced a $60 price target.

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and maintains $30 price target.

Price Target

Reiteration

ASPN

HC Wainwright & Co. Reiterates Buy on Aspen Aerogels, Maintains $30 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587639df5064ed0001400135/david-manthey">Baird analyst David Manthey</a> upgraded the rating for W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Neutral to Outperform and raised the price target from $975 to $1,230. Grainger shares closed at $1,085.57 on Tuesday. <a href="https://www.benzinga.com/quote/GWW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Begleiter upgraded Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Underperform to Neutral and boosted the price target from $151 to $159. Westlake shares closed at $141.80 on Tuesday. <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Atif Malik upgraded the rating for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Neutral to Buy and increased the price target from $52 to $62. Cisco shares closed at $54.08 on Tuesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cleveland Research upgraded the rating for SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) from Neutral to Buy. SAP shares closed at $229.52 on Tuesday. <a href="https://www.benzinga.com/quote/SAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and increased the price target from $13 to $22. WAVE Life Sciences shares closed at $8.56 on Tuesday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png" alt="" class="wp-image-599072" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130.png 1297w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Upgrades

CSCO

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Brookdale Senior Living shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a $8 price target.

HC Wainwright &amp; Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) with a Buy and maintains $28 price target.

CGEM

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target

Jefferies analyst Trevor Williams maintains WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) with a Hold and raises the price target from $190 to $210.

Jefferies Maintains Hold on WEX, Raises Price Target to $210

HC Wainwright &amp; Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) with a Buy and maintains $7 price target.

OKYO

HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target

PC maker Lenovo Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LNVGF#OTC">LNVGF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LNVGY#OTC">LNVGY</a>) tapped Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to enhance its artificial intelligence (AI) capabilities in markets outside China.
The U.S. semiconductor sanctions have barred China from accessing sophisticated AI chips from U.S. chip designers like Nvidia, citing national security threats. The embargo prompted Nvidia to develop the sanction-compliant <a target="_blank" href="https://www.benzinga.com/news/24/10/41317732/whats-going-on-with-nvidia-stock-on-monday" rel="noreferrer noopener">A800, H800, and H20 chips</a>.
At its annual Tech World conference in Seattle, Lenovo introduced AI Now, a personal AI assistant for PCs sold outside China, built on Meta&#8217;s open-source Llama 3.1 large language model, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3282586/lenovo-partners-meta-nvidia-ai-outside-china" rel="noreferrer noopener">reports</a>.
Lenovo&#8217;s AI assistant operates locally without an internet connection and can use natural language prompts to perform tasks like document management, text and image generation, and device configuration.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/10/41358664/whats-going-on-with-intel-stock-wednesday" rel="noreferrer noopener">What&#8217;s Going On With Intel Stock Wednesday?</a>
In addition to AI Now, Lenovo announced a deepened partnership with Nvidia to launch enterprise-focused AI solutions.
The new AI server, the Lenovo ThinkSystem SC777 V4 Neptune, features Nvidia&#8217;s Blackwell graphics processing units (GPUs) and Lenovo&#8217;s advanced water-cooling technology.
Lenovo faces ongoing risks tied to geopolitical tensions, particularly concerning supply chains. The company is leveraging AI to mitigate these risks through its AI-powered Supply Chain Intelligence solution, which has already reduced manufacturing and logistics costs by 20%.
Lenovo also introduced a new AI-powered PC, the ThinkPad X1 2-in-1 Gen 10 Aura Edition, and concept prototypes like the Lenovo &#8220;AI Buddy,&#8221; which assists users with daily tasks.
Lenovo reported a 20% jump in its first-quarter topline, reaching a revenue of <a target="_blank" href="https://investor.lenovo.com//en/financial/results.php" rel="noreferrer noopener">$15.4 billion</a>.
Canalys projects shipments of 44 million AI PCs in 2024, and IDC expects AI PC shipments to reach around 50 million during the year, Forbes <a target="_blank" href="https://www.forbes.com/sites/bethkindig/2024/09/12/ai-pcs-have-arrived-shipments-rising-competition-heating-up/" rel="noreferrer noopener">reported</a>.
For context, Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) are vying for the <a target="_blank" href="https://www.benzinga.com/news/24/08/40347392/apple-intel-and-amd-lead-charge-in-ai-capable-pc-market-surge-report" rel="noreferrer noopener">AI PC market</a> as Nvidia rules the AI data center market.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41357485/intel-partners-with-amd-to-counter-arms-rising-dominance-in-computing" target="_blank" rel="noreferrer noopener">Intel Partners With AMD To Counter Arm&#8217;s Rising Dominance in Computing</a></li>
</ul>
Photo by Robert Way via Shutterstock

Government

Regulations

Tech

Media

INTC

LNVGF

LNVGY

NVDA

Lenovo's AI Push Grows with Meta, Nvidia Collaboration Outside China

Most investors inconsistently view quarterly earnings as a catalyst for stock prices upon the news release. They often find themselves trapped in the volatility of sudden moves and face the risk of large&mdash;or total, in the case of options&mdash;losses if the direction of the stock after the announcement goes the wrong way.
There is a way to somewhat accurately predict where a stock could go after earnings announcements or to see where broader markets are betting these stocks could go on the event. Keeping the saying &quot;it must be expensive for a reason&quot; in mind can be useful for investors in these scenarios, likewise for cheapness. Here are three stocks becoming &lsquo;expensive&#39; before they report earnings this month and why markets are willing to pay.
Aerospace and defense stock Lockheed Martin Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lmt#NYSE">LMT</a>), wireless and communications provider T-Mobile US Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmus#NASDAQ">TMUS</a>), and even technology stock CoStar Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/csgp#NASDAQ">CSGP</a>) are some of the stocks reporting their subsequent quarrel earnings this month, and they all share the common factor of commanding valuation premiums compared to their peers. This is why markets might be willing to overpay for these stocks ahead of their announcements.
<h2>Lockheed Martin Positioned for Strong Quarter as Middle East Conflicts Drive Rising Arms Demand</h2>
As conflicts in the Middle East arise and escalate, the United States and its military allies will have to call upon domestic arms manufacturers like Lockheed Martin to help control and handle these situations accordingly, creating new demand for contracts in the company.
Investors can see this trend taking on momentum through a government contract database, spotting a new inflow of up to $599 million worth of government contracts going to Lockheed Martin to prepare responses against these conflicts, something markets are starting to bet on as the possibility of optimistic guidance and maybe even an earnings beat.
Knowing that a strong quarter is likely, markets are now willing to pay up to 21.5x the price-to-book (P/B) ratio, which is a significant premium over the rest of the aerospace sector&#39;s average valuation of 5.6x today. The optimism doesn&#39;t stop there for Lockheed Martin stock, though; others on Wall Street share the same bullish view.
Analysts at Citigroup decided to reiterate their &quot;Buy&quot; rating for the stock as recently as October 2024, this time seeing a price valuation of up to $700 a share. To prove these new views right, Lockheed Martin would need to rally by as much as 14.4% from where it trades today, not to mention a new 52-week high price for the company.
Lastly, investors can see signs of bearish capitulation in the face of all this bullish sentiment and evidence, as Lockheed Martin stock&#39;s short interest declined by as much as 18.8% over the past month alone, leaving room for new bulls to come in before the earnings are out.
<h2>T-Mobile Stock Gains New Premium as Subscription Business Strengthens</h2>
During times of higher inflation, such as today, and especially during economic uncertainty, businesses with subscription-based models tend to do well, considering their predictability and stability in cash flows and profits. Compared to peers like AT&amp;T Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>) and Verizon Communications Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vz#NYSE">VZ</a>), T-Mobile stands apart in strategy.
Competitors fell behind in investing heavily in fiber communications, which not only eat up a lot of cash but also pose significant weather risk, some of the issues that T-Mobile&#39;s fixed wireless model does not have to endure. Fixed wireless is less capital-intensive and safer, and that superior quality keeps the company a leadership state compared to peers.
This is also why markets are willing to overpay for T-Mobile stock ahead of its earnings announcement. Compared to the rest of the communications industry&#39;s average P/B ratio of 1.4x today, T-Mobile stock commands a premium of 3.9x today. Knowing that the business&#39; investments are superior to peers and that is drawing more business, markets are rightfully bullish before earnings.
Analysts at Benchmark have recently boosted their price targets for T-Mobile stock as well, this time shooting for $250 a share, which calls for up to 16% upside from where T-Mobile stock trades today.
<h2>Double-Digit Upside Ahead for CoStar Group Stock</h2>
Combining the power of data and technology to the real estate sector is CoStar&#39;s value proposition for investors, one Wall Street is surely bullish on before the company&#39;s next earnings announcement. Starting with analysts, here&#39;s what they say about the company&#39;s future.
Those at Needham &amp; Co. see CoStar Group stock trading as high as $107 a share, calling for a net upside of 38.4% from today&#39;s stock price, not to mention a new 52-week high. Knowing that the industry is in dire need of data to aid in decision-making during shifting interest rates, markets bet that the stock is going to deliver a strong quarter.
Looking into valuations, CoStar Group stock trades at 145.9x price-to-earnings (P/E) ratio today, compared to the rest of the business services industry&#39;s average 43.0x average P/E today. Another premium to consider ahead of earnings is to be justified by potential financial outperformance.
To close the loop on this view, investors can note CoStar Group stock&#39;s falling short interest, which declined by 4.6% during the past month alone. This shows investors another sign of bullishness through bearish capitulation in the stock recently.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-stocks-investors-dont-want-to-miss-ahead-of-earnings/">3 Stocks Investors Don&#39;t Want to Miss Ahead of Earnings</a>&quot; first appeared on MarketBeat.

Guidance

Contracts

Economics

CSGP

TMUS

3 Stocks Investors Don't Want to Miss Ahead of Earnings

Jefferies analyst Trevor Williams maintains Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) with a Buy and raises the price target from $375 to $425.

CPAY

Jefferies Maintains Buy on Corpay, Raises Price Target to $425

Macquarie analyst Tim Nollen maintains Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) with a Outperform and raises the price target from $110 to $120.

Macquarie Maintains Outperform on Omnicom Group, Raises Price Target to $120

Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) will take Plants vs. Zombies 3 offline, halting downloads and in-app purchases in preparation for a <a href="https://www.benzinga.com/general/gaming">&#8220;major overhaul.&#8221; </a>
The company announced that the game, which has gone through multiple soft launches since 2020, will be inaccessible from Nov. 15, 2024, in all territories. Players will have until that date to enjoy the game before the servers shut down completely.
See Also: <a href="https://www.benzinga.com/general/gaming/24/10/41319267/us-gaming-market-sees-7-spending-decline-in-august-madden-nfl-25-debut-a-bright-spot">US Gaming Market Sees 7% Spending Decline In August: Madden NFL 25 Debut A Bright Spot</a>
In a blog post addressing the changes, EA <a href="https://www.ea.com/games/plants-vs-zombies/plants-vs-zombies-3/news/soft-launch-announcement-15-oct?isLocalized=true">explained:</a> "We've been grateful for your enthusiasm and feedback during our soft launch. We've always had love for our plants, and yes, even our zombies, and it has been a joy bringing life to Dave, his niece, Patrice, Nate, and many more in PvZ3."
<h3 class="wp-block-heading">Game Progress And Currency Preservation</h3>
Despite the reset, EA reassured players that some aspects of their accounts will be preserved. Any earned or purchased coin balances will remain intact, provided players have connected their accounts through Google Play, Apple ID, or an EA Account. 
However, boosts, game progress, levels, and unlocked units, as well as the game&#8217;s narrative, will be reset once the overhaul is complete.
"We want to go even further to make the game truly special," EA stated, stressing the need for this downtime to deliver a more polished experience. It&#8217;s worth noting that there's no firm date for the game's re-launch.
<h3 class="wp-block-heading">The Ongoing Struggles Of Plants Vs. Zombies 3</h3>
Plants vs. Zombies 3 has experienced a turbulent development path, struggling to replicate the success of its predecessors. Initially soft-launched in 2020, the game underwent a significant re-work and re-launch in 2022. Yet, despite efforts to fine-tune the game, it still hasn't resonated with fans in the way EA had hoped.
The original Plants vs. Zombies franchise, beloved for its unique tower defense mechanics, set a high bar with its first two installments. More recent spin-offs, including the Plants vs. Zombies: Battle for Neighborville, have struggled to capture the same widespread acclaim.
<h3 class="wp-block-heading">Future Of The Franchise</h3>
Fans of the franchise have long been calling for a return to the Garden Warfare series, the third-person shooter spin-off that earned a dedicated following. However, there's been no official word from EA on a new Garden Warfare title, despite the franchise's current hiatus since 2019.
A separate single-player Plants vs. Zombies game, which had been in development at EA between 2015 and 2017, was also canceled.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/10/41129439/leaked-ea-project-rene-images-reveal-controversial-changes-why-the-sims-fans-are-furious">Leaked EA Project Rene Images Reveal Controversial Changes: Why The Sims Fans Are Furious</a></li>
</ul>
Image courtesy: EA

Gaming

Plants Vs. Zombies 3 Servers Shut Down As EA Plans 'Major Overhaul'

Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) will be reporting its third-quarter earnings on Thursday. Wall Street expects $5.12 in EPS and $9.77 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=NFLX" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 95.12% over the past year, 50.27% YTD.
Let&#8217;s examine the charts for Netflix stock and how it currently compares to Wall Street estimates.
<h2 class="wp-block-heading">Netflix Stock Bearish Near-Term, Bullish Long-Term Ahead Of Q3 Earnings </h2>
Netflix stock&#8217;s technical indicators present a mixed outlook, with the current trend leaning moderately bearish as the stock faces slight selling pressure. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16134509/Screenshot-2024-10-16-at-7.31.01-PM.png" alt="" class="wp-image-598922" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16134509/Screenshot-2024-10-16-at-7.31.01-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16134509/Screenshot-2024-10-16-at-7.31.01-PM-300x217.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
At $699.27, Netflix stock price falls below its eight-day and 20-day simple moving averages of $715.31 and $712.44, both signaling a bearish trend. 
However, the longer-term indicators tell a different story. The 50-day SMA of $690.78 and the 200-day SMA of $625.54 both present bullish signals, suggesting that the stock may have underlying strength. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16134540/Screenshot-2024-10-16-at-7.32.32-PM.png" alt="" class="wp-image-598923" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16134540/Screenshot-2024-10-16-at-7.32.32-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16134540/Screenshot-2024-10-16-at-7.32.32-PM-300x217.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The Moving Average Convergence Divergence (MACD) indicator, at 6.06, further supports a bullish case. While the Relative Strength Index (RSI) of 47.08 indicates the stock is neither overbought nor oversold. 
The stock remains within the Bollinger Bands range of $687.03 to $731.08, currently in the lower bearish band. However, the stock has mostly traded in the upper bullish band while only recently slipping lower, so an earnings beat may just be what Netflix stock needs to return to the bullish band again.
Read Also: <a href="https://www.benzinga.com/government/24/10/41364780/amazon-prime-video-india-to-introduce-ads-in-2025-intensifying-rivalry-with-reliance-and-disney">Amazon Prime Video India to Introduce Ads in 2025, Intensifying Rivalry with Reliance and Disney+</a>
<h2 class="wp-block-heading">Netflix Stock Analysts Bullish, See Limited Upside Though</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/NFLX/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Netflix stock is a Buy, with a price target of $720.50. The most recent analyst ratings for Netflix stock came from Loop Capital, Benchmark, and Guggenheim in mid-October. Their combined average price target of $718.33 indicates a potential 2.03% increase in Netflix&#8217;s stock value.
NFLX Price Action: Netflix stock was down 0.53% at $702.24 at the time of publication Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41341307/this-bearish-analyst-forecasts-huge-downside-for-netflix-cites-member-growth-risks-">This Bearish Analyst Forecasts Huge Downside For Netflix, Cites Member Growth Risks and Ad Monetization Concerns</a></li>
</ul>
Image via Unsplash

Entertainment

Technicals

Previews

NFLX

Netflix Stock Stumbles, But Q3 Earnings Could Flip The Script For Investors

Jefferies analyst Trevor Williams maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Hold and raises the price target from $80 to $90.

Jefferies Maintains Hold on Fidelity National Info, Raises Price Target to $90

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Neutral.

ACET

HC Wainwright & Co. Reiterates Neutral on Adicet Bio

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains the...

NovoCure Leadership Transition Signals Stability and Earns Buy Rating

Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025

NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM

Novocure gets FDA approval for its lung cancer treatment

NovoCure ( ($NVCR) ) has shared an update. The FDA has approved Novocure's Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in treating m...

FDA Approves NovoCure Device for mNSCLC Treatment

Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains t...

Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune's Market Potential

H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of $30.00. Emi...

NovoCure's Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion

Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00. The company...

Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)

Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of $28.00. Jo...

NovoCure's Growth Potential Boosted by FDA Approval and Market Expansion

NovoCure: There Is Still More Upside

ARGNF

ARGX

NVCR

ZLAB

Press Releases

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

Novocure to Report Second Quarter 2024 Financial Results

CereVasc Announces Appointments of New Directors

Novocure Reports Second Quarter 2024 Financial Results

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

Novocure Announces Planned CEO Transition

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Novocure to Report Third Quarter 2024 Financial Results

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

PODD

Artivion

Alphatec Holdings

AtriCure

Axogen

Axonics

CeriBell

Conmed

Enovis

Paragon 28

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

iRadimed

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

LeMaitre Vascular

Inari Medical

Envista Holdings Corporation Common Stock

Envista Holdings

Orthofix Medical

Omnicell

Pulse Biosciences

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

SI-BONE

Surmodics

TransMedics Gr

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

HC Wainwright & Co.

Evercore ISI Group

Wells Fargo

Piper Sandler

JP Morgan

NovoCure shares are trading higher after the company announced FDA approval of Optune Lua for the treatment of metastatic non-small cell lung cancer. Also, HC Wainwright & Co. upgraded the stock from Neutral to Buy and raised its price target from $24 to $30.

Comments

NovoCure

Intérêt court

NovoCure (NASDAQ:NVCR) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL